Buddeberg Bigna S, Seeberger Manfred D
Clinic for Anesthesia, Intermediate Care, Prehospital Emergency Medicine and Pain Therapy, University Hospital Basel, Basel, Switzerland.
Medical School, University of Basel, Basel, Switzerland.
Front Oncol. 2022 Mar 14;12:802210. doi: 10.3389/fonc.2022.802210. eCollection 2022.
Cancer is a leading cause of death, and surgery is an important treatment modality. Laboratory research and retrospective studies have raised the suspicion that the choice of anesthetics for cancer surgery might affect the course of cancerous disease. The aim of this review is to provide a critical overview of the current state of knowledge. Inhalational anesthesia with volatiles or total intravenous anesthesia (TIVA) with propofol are the two most commonly used anesthetic techniques. Most data comparing volatile anesthetics with TIVA is from either or retrospective studies. Although conflicting, data shows a trend towards favoring propofol. Opioids are commonly used in anesthesia. Data on potential effects of opioids on growth and recurrence of cancer are scarce and conflicting. Preclinical studies have shown that opioids stimulate cancer growth through the µ-opioid receptor. Opioids also act as immunosuppressants and, therefore, have the potential to facilitate metastatic spread. However, the finding of an adverse effect of opioids on tumor growth and cancer recurrence by some retrospective studies has not been confirmed by prospective studies. Regional anesthesia has not been found to have a beneficial effect on the outcome of surgically treated cancer patients, but prospective studies are scarce. Local anesthetics might have a beneficial effect, as observed in animal and studies. However, prospective clinical studies strongly question such an effect. Blood products, which may be needed during extensive cancer surgery suppress the immune system, and data strongly suggest a negative impact on cancer recurrence. The potential effects of other commonly used anesthetic agents on the outcome of cancer patients have not been sufficiently studied for drawing valid conclusions. In conclusion, laboratory data and most retrospective studies suggest a potential advantage of TIVA over inhalational anesthesia on the outcome of surgical cancer patients, but prospective, randomized studies are missing. Given the state of weak scientific evidence, TIVA may be used as the preferred type of anesthesia unless there is an individual contraindication against it. Studies on the effects of other drugs frequently used in anesthesia are limited in number and quality, and have found conflicting results.
癌症是主要的死亡原因之一,手术是一种重要的治疗方式。实验室研究和回顾性研究引发了人们对于癌症手术麻醉剂的选择可能会影响癌症病程的怀疑。本综述的目的是对当前的知识状况进行批判性概述。挥发性吸入麻醉或丙泊酚全静脉麻醉(TIVA)是两种最常用的麻醉技术。大多数比较挥发性麻醉剂和TIVA的资料来自回顾性研究。尽管存在矛盾,但数据显示出倾向于丙泊酚的趋势。阿片类药物常用于麻醉。关于阿片类药物对癌症生长和复发的潜在影响的数据稀少且相互矛盾。临床前研究表明,阿片类药物通过μ-阿片受体刺激癌症生长。阿片类药物还具有免疫抑制作用,因此有可能促进转移扩散。然而,一些回顾性研究发现阿片类药物对肿瘤生长和癌症复发有不良影响,但前瞻性研究并未证实这一点。尚未发现区域麻醉对接受手术治疗的癌症患者的预后有有益影响,但前瞻性研究较少。局部麻醉剂可能有有益作用,如在动物和体外研究中观察到的那样。然而,前瞻性临床研究对这种作用提出了强烈质疑。在广泛的癌症手术中可能需要的血液制品会抑制免疫系统,数据强烈表明其对癌症复发有负面影响。对于其他常用麻醉剂对癌症患者预后的潜在影响,尚未进行充分研究以得出有效结论。总之,实验室数据和大多数回顾性研究表明,在手术癌症患者的预后方面,TIVA相对于吸入麻醉可能具有潜在优势,但缺乏前瞻性随机研究。鉴于科学证据薄弱的状况,除非有个体禁忌,TIVA可作为首选的麻醉类型。关于麻醉中常用的其他药物的影响的研究数量和质量有限,且结果相互矛盾。